Form 4: Cytek Biosciences Chief Legal Officer Reports Stock Transactions

Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported the vesting of restricted stock units and the subsequent withholding of shares to cover tax obligations on November 18, 2024.

Summary

• Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reported transactions involving restricted stock units (RSUs) on November 18, 2024.
• The transactions included the vesting of 2,016, 3,681, and 7,735 RSUs, which convert to common stock.
• A portion of the vested shares, specifically 661, 1,235, and 2,603 shares, were withheld to satisfy tax obligations at a price of $6.03 per share.
• Following these transactions, Ms. Barnett beneficially owns 62,850 shares of common stock directly.
• The RSUs vest over four years, with varying vesting schedules.

Sentiment

Score: 7

Explanation: The document reflects routine executive compensation transactions, which are neither particularly positive nor negative. The sentiment is neutral to slightly positive as it indicates the executive is receiving compensation.

Positives

• The vesting of restricted stock units is a standard part of executive compensation.
• The reporting of these transactions is in compliance with SEC regulations.

Risks

• The sale of shares to cover tax obligations could potentially exert downward pressure on the stock price, although the number of shares is relatively small.
• The vesting schedule of the RSUs could lead to further transactions in the future.

Industry Context

This is a routine filing related to executive compensation and is common in publicly traded companies. It reflects the standard practice of granting restricted stock units to executives as part of their compensation packages.

Comparison to Industry Standards

• The use of restricted stock units as part of executive compensation is a common practice among publicly traded companies, including those in the biotechnology and life sciences sectors.
• Companies like Illumina, Thermo Fisher Scientific, and Danaher also use similar equity-based compensation plans for their executives.
• The vesting schedules and tax withholding practices are generally consistent with industry norms.

Stakeholder Impact

• The transactions have a minor impact on shareholders due to the small number of shares involved.
• The vesting of RSUs is a positive for the executive, Valerie Barnett.

Key Dates

Keywords

Cytek Biosciences, Restricted Stock Units, SEC Form 4, Valerie Barnett, Stock Transactions, Executive Compensation, Vesting, Tax Withholding